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What is already known about this topic? Primary care physicians are often reticent to refer patients with asthma to
specialist care, because they are working under the expectation that all asthma can be managed effectively in primary
care and/or are unaware of the benefits of referral.
What does this article add to our knowledge? There are large numbers of patients with asthma in the United Kingdom
with potential severe asthma (8%) who are managed long-term in primary care who may be eligible for referral to specialist
care.
How does this study impact current management guidelines? Our findings may help primary care physicians
recognize those with hidden severe asthma in their care. These patients would benefit from a structured assessment by
their primary care physician, with possible referral to specialist care.sher Institute, University of Edinburgh, United Kingdom
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GINA- Global INitiative for Asthma
ICS- inhaled corticosteroidISAR- International Severe Asthma Registry
LABA- long-acting b2-agonist
PSA- potential severe asthma
OCS- oral corticosteroidOPCRD-Optimum Patient Care Research Database
UKSAR- UK Severe Asthma RegistryBACKGROUND: Severe asthma may be underrecognized in
primary care.
OBJECTIVE: Identify and quantify patients with potential
severe asthma (PSA) in UK primary care, the proportion not
referred, and compare primary care patients with PSA with
patients with confirmed severe asthma from UK tertiary care.
METHODS: This was a historical cohort study including
patients from the Optimum Patient Care Research Database
(aged ‡16 years, active asthma diagnosis pre-2014) and UK
patients in the International Severe Asthma Registry (UK-ISAR
aged ‡18 years, confirmed severe asthma in tertiary care). In the
OPCRD, PSA was defined as Global INitiative for Asthma 2018
step 4 treatment and 2 or more exacerbations/y or at Global
INitiative for Asthma step 5. The proportion of these patients
and their referral status in the last year were quantified. De-
mographic and clinical characteristics of groups were compared.
RESULTS: Of 207,557 Optimum Patient Care Research
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/10.1016/j.jaip.2020.11.053these, 72% had no referral/specialist review in the past year.
Referred patients with PSA tended to have greater prevalence
of inhaled corticosteroid/long-acting b2-agonist add-ons (54.1
vs 39.8%), and experienced significantly (P < .001) more ex-
acerbations per year (median, 3 vs 2/y), worse asthma control,
and worse lung function (% predicted postbronchodilator
FEV1/forced vital capacity, 0.69 vs 0.72) versus nonreferred
patients. Confirmed patients with severe asthma (ie, UK pa-
tients in the International Severe Asthma Registry) were
younger (51 vs 65 years; P < .001), and significantly (P < .001)
more likely to have uncontrolled asthma (91.4% vs 62.5%), a
higher exacerbation rate (4/y [initial assessment] vs 3/y), use
inhaled corticosteroid/long-acting b2-agonist add-ons (67.7%
vs 54.1%), and have nasal polyposis (24.2% vs 6.8) than
referred patients with PSA.
CONCLUSIONS: Large numbers of patients with PSA in the
United Kingdom are underrecognized in primary care. These
patients would benefit from a more systematic assessment in
primary care and possible specialist referral.  2020 The
Authors. Published by Elsevier Inc. on behalf of the
American Academy of Allergy, Asthma & Immunology. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). ( J
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Appropriate and timely review of patients with difficult-to-
treat asthma in specialist care is a key aspect of asthma
management, improving outcomes and access to additional
health care resources and advanced therapies.1,2 A specialist care
review facilitates an accurate diagnosis, permits identification and
control of comorbidities, triggers, poor adherence and inhaler
technique, determination of specific asthma phenotypes, and
diagnosis of severe asthma.3,4 Although much of this can be done
in primary care using a structured approach to review patients
with uncontrolled asthma,5 that is often not the case. Asthma
management guidelines provide guidance on when patients with
asthma should be reviewed.6 However, despite these guidelines,
failure to refer for specialist consultation is evident.7,8 Indeed, the
National Review of Asthma Deaths reported that 19% of deaths
attributable to asthma in the United Kingdom were associated
with potentially avoidable factors related to access to specialist
care, such as failure to refer or delayed referral.9 Certainly those
suspected of having severe asthma should be reviewed in
specialist care, but how are these patients with potential severe
asthma (PSA) identified?
The true size of the severe asthma population remains
unknown. It could be overestimated—a reflection of incorrect
inhaler use and poor medication adherence.10-12 However, it
may be underestimated because of differences in definition and
diagnostic practices around the world, or it may be a function of
how asthma is managed nationally. For example, there may be
downward pressure on primary care not to make referrals or
some other form of disincentive to refer. Alternatively, patients
with severe asthma may have been previously discharged from
specialist care back to primary care and managed with long-term
maintenance or recurrent courses of oral corticosteroids (OCSs)
or at Global INitiative for Asthma (GINA) 20184 step 4 treat-
ment with frequent exacerbations. There is a need to identify and
understand this potential “hidden” primary care severe asthma
population, because these patients may benefit from specialist
review and specialist treatments (eg, biologic therapy) but be
unable to access it in primary care.
To shed light on this issue, one approach is to identify PSA in
a primary care electronic health records database and compare
these patients to those with a specialist-confirmed severe asthma
diagnosis in the same country. This approach requires existing
primary and tertiary care databases with sufficient numbers of
patients and a consistent definition of severe asthma. Data
should be anonymized and of high quality, and variables
collected should be similar between databases to facilitate cross-
comparison. This situation exists in the United Kingdom,
home to both the Optimum Patient Care Research Database
(OPCRD)13 and the UK Severe Asthma Registry
(UKSAR), included in the International Severe Asthma Registry
(ISAR).14
The OPCRD is a primary care electronic health care records
database. It comprises medical records of more than 9.7 million
patients (as of April 2020) from more than 700 general practices
across the United Kingdom (w13.2% of the total UK popula-
tion) and integrates with all UK clinical systems (EMIS, TPP
SystmOne, InPS Vision, Microtest Evolution).13 ISAR is the first
global, adult, severe asthma registry.14 It is a multicenter,
multinational, observational initiative based in tertiary care that
collects a standardized set of variables (agreed by Delphi
1614 RYAN ETALconsensus) prospectively and retrospectively on patients with
severe asthma.15-18
The aims of this study were to (1) identify patients with PSA
managed in UK primary care, (2) estimate how many of these
may be effectively “hidden” (ie, not reviewed or currently
managed in specialist care), and (3) compare the demographic
and clinical characteristics of patients with PSA with those of
patients with a confirmed severe diagnosis managed in regional
specialist centers in the United Kingdom and included in ISAR.
METHODS
Study design
This was a historical cohort study, using data from the OPCRD13
and from UK patients in ISAR.14 Patients in primary care with PSA
(see patient cohort definitions) were identified from the OPCRD.
Asthma-related outcome measures within the OPCRD have been
validated using patient-reported outcomes.19 Patients in tertiary care
with confirmed severe asthma were those registered in the UKSAR
and included in the ISAR (http://isaregistries.org/). UKSAR has
received ethics approval to provide deidentified data to ISAR in
compliance with UK-specific international data transfer laws and
legislation.17,18 ISAR captures 95 core variables agreed by Delphi
consensus.15 The current study protocol was approved by the
Anonymised Data Ethics Protocols And Transparency committee
(ADEPT0319) and registered with the European Union electronic
Register of Post-Authorization studies (EUPAS28611).20
Inclusion criteria
Patients included from the OPCRD (ie, primary care) were
required to be 16 years or older, have an active current diagnosis of
asthma (before 2014 and no subsequent recorded asthma resolved
Read Code after the latest asthma diagnosis), have received 1 or
more asthma medication during the 1-year follow-up period, and
have 1 or more year of data from 2014 onward (to align with the
ISAR data collection period). Patients with physician-confirmed
diagnosis of other respiratory conditions were excluded. Those
with a confirmed severe asthma diagnosis included all UK patients
registered in ISAR. Inclusion in ISAR requires that patients are 18
years or older and are receiving GINA (2018)4 step 5 treatment or
have uncontrolled asthma at GINA 2018 step 4 (eg, 2 exacerba-
tions/y). These patients have been assessed by a specialist to ensure
correct diagnosis and optimum management (including identifica-
tion of triggers, drug therapy, correct use of device(s), adherence, and
comorbidities).
Patient cohort definitions
The following patient cohorts were defined:
1. PSA reviewed/referred from the OPCRD cohort. These were
patients (aged 16 years) in primary care receiving GINA 20184
step 4 treatment and experiencing 2 or more exacerbations/y or
receiving GINA 2018 step 5 treatment and who had been
reviewed by, or received a referral to, a respiratory specialist in the
last year.
2. PSA NOT reviewed/referred from the OPCRD cohort. As for
above, but these patients had not been reviewed by, or referred to,
a respiratory specialist in the last year.
3. Confirmed patients with severe asthma from the ISAR cohort.
Patients (aged 18 years) managed in regional specialist centers,
registered in the UKSAR and included in ISAR.
TABLE I. Description of key outcome variables presented
Variable Description
Comorbidities  For UK-ISAR, comorbidities are captured in
free text, and so are likely underreported
(particularly when compared with the patients’
long-term primary care record)
 OPCRD: comorbidities are coded
Exacerbation  Worsening of asthma requiring systemic
corticosteroids
Asthma control  OPCRD: assessed 5 ways:
1. Royal College of Physicians questionnaire21
2. Asthma Control Test22
3. Risk Domain Asthma Control19
4. Overall Asthma Control
5. Short-acting b2-agonist use
 UK-ISAR: assessed by the Asthma Control
Questionnaire23
Adherence  OPCRD: assessed using the medication
possession ratio, with good adherence to
treatment defined as a ratio 70% (based on
ICS prescription refills).24
 UK-ISAR: assessed by asking the question, “is
there evidence of poor adherence?” during
systematic assessments, which was answered
as “clinical impression,” “prescription re-
cords,” “objective measures,” or “no.”
J ALLERGY CLIN IMMUNOL PRACT
VOLUME 9, NUMBER 4
RYAN ETAL 1615Study outcomes
OPCRD patients with active asthma (aged 16 years) with 1 or
more asthma medication were categorized according to GINA 20184
treatment step and number of exacerbations experienced/y. The
proportion of patients in the OPCRD with PSA (with/without
specialist review/referral in the last year) was quantified. De-
mographic and clinical characteristics were described for each patient
cohort, using data from the latest available year for all outcomes.
Demographic outcomes included age, sex, race, body mass index,
and smoking history. Clinical outcomes included exacerbations/y,
asthma control, lung function, asthma treatments, adherence,
comorbidities (ie, allergic rhinitis, eczema, nasal polyps), and blood
eosinophil count (BEC). Definitions of outcomes assessed are
presented in Table I (full details in Table E1 in this article’s Online
Repository at www.jaci-inpractice.org).
Statistics
Primary analyses. OPCRD data were assessed using Stata
MP/6 version 15.1 (StataCorp LLC, College Station, Texas) and
data for UK patients in the International Severe Asthma Registry
(UK-ISAR) using Stata version 14 (College Station, Texas) or SAS
version 9.4/9.5 (Cary, NC). Descriptive statistics for demographic
and clinical characteristics for each patient cohort from the OPCRD
and UK-ISAR were provided for continuous and categorical vari-
ables as either n (%) or mean (95% CI) and median (25th, 75th
percentile), as appropriate. Mean values were compared using a t
test, median values using Wilcoxon-Mann-Whitney, and categori-
cal values suing c2 or Fishers exact for variables with small (ie, <5)
values. A P value of less than .05 was considered statistically sig-
nificant. The proportion of patients with PSA (n, %) (1) referred/
reviewed in the last year and (2) not referred/reviewed in the last
year was also calculated. Referral was defined as a referral code in
OPCRD to a respiratory specialist.Sensitivity analyses. The proportion of patients with 0, 1, 2,
3, 4, and 5 or more exacerbations/y was calculated for the PSA
referred patient cohort, for those 16 years and older and 18 years
and older, in the year before a referral to better understand referral
drivers. In addition, for those OPCRD patients who were not
referred/reviewed in the last year, a post hoc analysis was conducted
to quantify the proportion of patients not referred/reviewed ever
during the OPCRD look-back period (mean, 19.2 years; 95% CI,
19.1-19.3). Finally, the demographic and clinical characteristics of
patients in each OPCRD cohort were described for patients 18
years and older and for those with a more than 5-year OPCRD
look-back period. The former analysis was conducted to align with
UK-ISAR age inclusion criterion and to facilitate cross-comparison
between OPCRD and ISAR data. The latter analysis was a
sensitivity analysis to determine whether the look-back period had
an impact on demographic and clinical characteristic outcomes.
Highest BEC recorded was also assessed for each patient cohort
post hoc.RESULTS
Study population
From an initial 900,785 patients in the OPCRD with a
diagnosis of asthma before 2014 (and no other respiratory
diagnosis), 207,557 patients met all inclusion criteria and were
included in the analysis (Figure 1). Overall, 17.5%, 41.6%, and
2.6% of patients were receiving treatment at GINA 20184 step
3, 4, and 5, respectively. The number of exacerbations per year
increased with treatment step (Figure 2). As expected, most
patients receiving GINA step 5 treatment experienced 2 or
more exacerbations/y, but many patients at lower GINA
steps also experienced multiple exacerbations per year. A
summary of asthma treatment by GINA 20184 step is provided
in Table E2 in this article’s Online Repository at www.jaci-
inpractice.org.Quantification and referral status of patients with
PSA managed in UK primary care
A total of 8% (16,409 of 207,557) of patients with active
asthma in UK primary care (aged 16 years) were found to
have PSA (Figure 3); or 4% of patients (16,409 of 416,125) if
one considers all patients (aged 16 years) with a diagnosis of
asthma (not necessarily active). Overall, 10,963 of these 16,409
patients were at GINA 2018 step 4 and 2 or more exacerbations
and 5446 were at GINA 2018 step 5. Of the 8% of
patients with PSA, 72% (11,741 of 16,4096) had not been
reviewed by or referred to a specialist in the past year; 56%
(9,113) had no record of specialist referral or review ever during
the OPCRD look-back period (mean, 19.2 years; 95% CI,
19.1-19.3). The remaining 16% of patients (n ¼ 2628) had
been referred or reviewed in specialist care, but more than 1
year ago (mean time since last review, 1.89 years) (Figure 3; see
Figure E1 in this article’s Online Repository at www.jaci-
inpractice.org).
There were other patient cohorts within the OPCRD active
asthma population that, despite not meeting the strict PSA
criteria, nevertheless continued to experience 2 or more exacer-
bations/y at GINA 2018 step 3 (1%; n ¼ 1,889 of 207,557) or
were at GINA 2018 step 4 with 0 exacerbation/y (29%; 60,425
of 207,557) or 1 exacerbation/y (7%; n ¼ 14,917 of 207,557).
FIGURE 1. OPCRD subject disposition.
FIGURE 2. Number of exacerbations experienced by OPCRD patients (n ¼ 207,557) by GINA 2018 treatment step.
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Characteristics of patients with PSA in primary
care. Patients with PSA managed in UK primary care tended to
be female, in their 60s, and overweight/obese (Table II). More
than 70% of them were current or ex-smokers. These patients
exhibited significant morbidity. Lung function was poor. More
than 50% of patients had evidence of irreversible obstruction
(ie, postbronchodilator FEV1/forced vital capacity <0.7), and
more than 60% of patients had a postbronchodilator peak
expiratory flow rate less than 80% predicted. Although patientswith PSA experienced a median of 2 to 3 exacerbations/y
(Table II), not all patients with PSA experienced multiple
exacerbations/y prereferral (Figure 4). Most had poorly
controlled disease (>60% of patients were prescribed 4 short-
acting b2-agonist inhalers in the past year), despite treatment
with ICS/long-acting b2-agonist (ICS/LABA) (>40% patients)
and add-on therapy (ie, leukotriene receptor antagonist and/or
long-acting muscarinic receptor antagonist) for more than 40%
of patients (Table II; Figure 5). Multimorbidity was also a feature
of this population, most commonly allergic rhinitis and eczema
(one-third of patients for each) (Table II).
FIGURE 3. Proportion of patients with active asthma (age 16 years) managed in UK primary care with potential severe disease and their
referral status. *During the OPCRD look-back period (mean, 19.2 years; 95% CI, 19.1-19.3).
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not referred/reviewed in specialist care. Compared
with patients with PSA who were referred to or reviewed by a
specialist in the preceding year, those without a referral/review
experienced significantly fewer exacerbations (median 2 vs 3/y;
P < .001) in the last year (after referral) and had fewer pre-
scriptions for add-ons to ICS/LABA therapy (39.8% vs 54.1% of
patients; Figure 5). However, many referred patients with PSA
(45.3%) experienced 0 exacerbations before referral (Figure 4).
There was no significant difference in postbronchodilator FEV1/
forced vital capacity ratios between patients with PSA with and
without a referral/review. Although patients with PSA without a
referral/review also experienced significantly (P < .001) worse
asthma control and lung function, were more likely (P < .001)
to suffer from allergic rhinitis and anxiety/depression, and were
less likely (P < .05) to have chronic rhinitis, diabetes, osteopo-
rosis, and heart failure compared with referred patients with PSA,
these differences were small (Table II; see Figure E2 in this ar-
ticle’s Online Repository at www.jaci-inpractice.org).PSA in primary care vs confirmed severe asthma in
tertiary care. Compared with patients with PSA (aged 18
years) in primary care who were referred/reviewed by a specialist
in the preceding year, patients with confirmed severe asthma
(aged 18 years) managed in tertiary care were significantly
(P < .001) younger, significantly (P < .001) more likely to have
never smoked and to be of wider race diversity (Table II),
reported more exacerbations and frequency (at first assessment)
(Table II; Figure 4), have uncontrolled asthma (Table II;Figure E2), be prescribed add-ons to ICS/LABA therapy
(Figure 5), and have nasal polyps and anxiety/depression, but less
likely to have AR or eczema (Table II). Interestingly, those in
tertiary care and referred patients with PSA from primary care
had almost identical lung function and the proportions of
patients with irreversible obstruction were similar in both groups.
A total of 55% of patients with severe asthma managed in tertiary
care were treated with biologics (Table II).
Sensitivity analyses
The results were similar for OPCRD cohorts 18 years or older
(vs 16 years) and did not markedly differ from those with an
OPCRD look-back period of more than 5 years (see Table E3 in
this article’s Online Repository at www.jaci-inpractice.org).
DISCUSSION
In this study we have introduced a classification of PSA for
patients with asthma managed in primary care and quantified
this population in the UK on the basis of well-defined primary
care electronic medical records, described their demographic and
clinical characteristics, and analyzed the respiratory specialist
referral/review landscape. Using this approach, 8% of patients
with active asthma managed in UK primary care had strong
evidence of severe asthma and could benefit from referral to/re-
view by an asthma specialist. However, 72% had neither been
referred nor received specialist care for over a year, and 56% of
patients had never been referred to or reviewed by a specialist
from their inclusion in the OPCRD (mean, 19 years look-back
period). Other primary care patient cohorts were also
identified; patients with active asthma at GINA 2018 step 4
TABLE II. Demographic and clinical characteristics of patients with PSA (aged 16 years) in UK primary care (OPCRD) vs those UK




Primary care (OPCRD) Tertiary care (UK-ISAR)
P value
PSA not reviewed or
referred in specialist
care (age ‡16 y)
PSA reviewed/referred
in specialist care in last
year (age ‡16 y)
PSA reviewed/referred in
specialist care in last
year (age ‡18 y)
Confirmed severe
asthma (age ‡18 y)
Demographic
characteristic
N ¼ 11,741 N ¼ 4,668 N ¼ 4,634 N ¼ 714
Age (y) .001
Mean (95% CI) 62 (62.0-62.7) 63 (62.1-63.2) NS 63 (62.4-63.4) 50 (48.8-50.8)
Median (25th, 75th
percentile)
65 (51, 76) 65 (51, 76) 65 (51, 76) 51 (40, 60)
Female, n (%) 7,672 (65.3) 3,040 (65.1) NS 3,019 (65.1) 458 (64.1) NS
Race, n (%) N ¼ 5,093 N ¼ 2,984 NS N ¼ 2,961 .001
White 3,144 (61.7) 1,821 (61.0) 1,806 (61.0) 488 (68.3)
Black 46 (0.9) 47 (1.6) 46 (1.5) 50 (7.0)
Asian 1 (0.0) 2 (0.1) 2 (0.1) 82 (11.5)
Other 22 (0.4) 14 (0.5) 14 (0.5) 94 (13.2)
Unknown 1,880 (36.9) 1,100 (36.9) 1,093 (36.9) 0 (0.0)
Body mass index N ¼ 10,417 N ¼ 3,962 NS N ¼ 3,933 NS
Mean (95% CI) 29.2 (29.1-29.4) 29.4 (29.2-29.7) 29.5 (29.2-29.7) 30.7 (30.2-31.3)
Median (25th, 75th
percentile)
28.2 (24.3, 33.1) 28.3 (24.2, 33.3) 28.3 (24.2, 33.4) 29.5 (25.8, 34.6)
Underweight
(<18.5), n (%)
321 (3.1) 133 (3.4) 130 (3.3) 5 (0.7)
Normal weight
(18.5-<25), n (%)
2,743 (26.2) 1,039 (26.2) 1,026 (26.1) 144 (20.2)
Overweight (25-
<30), n (%)
3,249 (31.0) 1,192 (30.1) 1,186 (30.1) 226 (31.6)
Obese (30), n (%) 4,104 (39.2) 1,598 (40.3) 1,591 (40.5) 339 (47.5)
Smoking status, n (%) N ¼ 11,674 N ¼ 4,637 .001 N ¼ 4,603 N ¼ 712 .001
Never 2,945 (25.2) 1,021 (22.0) 1,001 (21.7) 492 (69.1)
Current 2,459 (21.1) 914 (19.7) 910 (19.8) 29 (4.1)





Mean (95% CI) 2.36 (2.33-2.39) 3.22 (3.15-3.28) 3.21 (3.15-3.28) 5.13 (4.83-5.44)*
Median (25th, 75th
percentile)
2 (2, 3) 3 (2, 4) 2 (3,4) 4 (2, 7)
Asthma control
Asthma control RCP, n
(%)
N ¼ 5,000 N ¼ 2,941 .001 N ¼ 2,920 —
Controlled 2,312 (46.2) 1,015 (34.5) 1,008 (34.5) —
Partial control — — — —
Not controlled 2,688 (53.8%) 1,926 (65.5%) 1,912 (65.5%) —
Asthma control ACT, n
(%)
N ¼ 664 N ¼ 448 .001 N ¼ 445 N ¼ 690† .001
Well controlled 58 (8.7) 19 (4.2) 19 (4.3) 33 (4.8)
Reasonably 262 (39.5) 151 (33.7) 148 (33.2) 26 (3.8)




Controlled 1,586 (13.5) 337 (7.2) 330 (7.1) — —
Not controlled 10,155 (86.5) 4,331 (92.8) 4,304 (92.9) —











Primary care (OPCRD) Tertiary care (UK-ISAR)
P value
PSA not reviewed or
referred in specialist
care (age ‡16 y)
PSA reviewed/referred
in specialist care in last
year (age ‡16 y)
PSA reviewed/referred in
specialist care in last
year (age ‡18 y)
Confirmed severe
asthma (age ‡18 y)
Controlled 928 (7.9) 150 (3.2) 144 (3.1) —
Not controlled 10,813 (92.1) 4,518 (96.8) 4,490 (96.9) —
SABA use, n (%) .001 —
<4 inhalers 4,284 (36.5) 1,428 (30.6) 1,424 (30.7) —
4 inhalers (not
controlled)
7,457 (63.5) 3,240 (69.4) 3,210 (69.3) —




N ¼ 5,149 N ¼ 2,405 N ¼ 2,398 N ¼ 653
Mean (95% CI) 0.72 (0.71-0.72) 0.69 (0.68-0.70) 0.69 (0.68-0.70) 0.70 (0.68-0.72)
Patients with
postbronchodilator
FEV1 >80%, n (%)




N ¼ 4,021 N ¼ 1,931 .001 N ¼ 1,926 N ¼ 643 NS
Mean (95% CI) 0.85 (0.84-0.85) 0.82 (0.81-0.83) 0.82 (0.81-0.83) 0.87 (0.85-0.88)
Postbronchodilator
FEV1/FVCz
N ¼ 5,249 N ¼ 2,503 NS N ¼ 1,709 N ¼ 697 NS
Mean (95% CI) 0.78 (0.72-0.90) 0.78 (0.72-0.92) 0.78 (0.72-0.90) 0.66 (0.65-0.68)
<0.70, % 52.4 53.4 53.4 56.4
% predicted PEF rate N ¼ 2,498 N ¼ 1,678 NS N ¼ 1,678 — —
Mean (95% CI) 0.75 (0.74-0.76) 0.73 (0.72-0.74) 0.73 (0.72-0.74)
80%, n (%) 964 (38.3) 636 (37.6) 629 (37.5)
BEC
N ¼ 11,147 N ¼ 4,458 NS N ¼ 4,442 N ¼ 712
Median BEC (25th,
75th percentile)




260 (160-400) 270 (170-400) 270 (170-400) 278 (269-287) NS
Other treatments, n (%)
Theophylline 935 (8.0) 640 (13.7) NS 636 (13.7) 173 (24.2) NS
Biologics 0 (0.0) 19 (0.2) 10 (0.2) 393 (55.0)
Adherence, n (%)
N ¼ 4,303 N ¼ 4,303 .001 N ¼ 4,279 N ¼ 708x .001
70% MPR of ICS 5,176 (51.6) 2,416 (56.1) 2,403 (56.2) 520 (73.4)
Comorbidities, n (%)jj
Allergic rhinitis 3,660 (31.2) 1,245 (26.7) .001 1,238 (26.7) 33 (4.6) .001
Chronic rhinosinusitis 495 (4.2) 241 (5.2) .05 239 (5.1) NA —
Eczema 3,822 (32.5) 1,456 (31.3) NS 1,445 (31.2) 20 (2.8) .001
Nasal polyps 801 (6.8) 317 (6.8) NS 316 (6.8) 173 (24.2) .001
Anxiety/depression 191 (1.6) 39 (0.8) .001 39 (0.8) 20 (2.8) .001
Diabetes 1,058 (9.0) 585 (12.6) .001 585 (12.6) 2 (0.3) .001
GERD 2,324 (19.7) 970 (20.7) NS 968 (20.8) NA NS
Osteoporosis 928 (7.9) 431 (9.3) .05 431 (9.3) 2 (0.3) .001
Heart failure 424 (3.6) 212 (4.6) .05 212 (4.6) 1 (0.1) .001
ACT, Asthma Control Test; FVC, forced vital capacity; MPR, medication possession ratio; NA, not applicable/available; NS, not significant; OAC, overall asthma control; PEF,
peak expiratory flow; RCP, Royal College of Physicians; RDAC, Risk Domain Asthma Control; SABA, short-acting b2-agonist.
*At first assessment.
†Assessed by the Asthma Control Questionnaire.
zAge-standardized FEV1/FVC ratios.
xAdherence assessed via the probe question, “is there evidence of poor adherence.”
jjOPCRD: based on having a diagnosis at any point in time; ISAR: patient self-reported.
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FIGURE 4. Proportion of patients in each cohort according to number of exacerbations experienced per year. UK-ISAR, UK patients in the
ISAR. *For those patients referred to specialist care, the exacerbation rate is the rate in the year before referral.
FIGURE 5. Proportion of patients in each cohort on a multiple asthma treatment regimen. LAMA, Long-acting muscarinic receptor
antagonist; LTRA, leukotriene receptor antagonist; UK-ISAR, UK patients in the ISAR.
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patients may be overtreated and could benefit from treatment
step-down pending review of control status. Furthermore, 8% of
patients were either receiving GINA 2018 step 3 treatment with
2 or more exacerbations/y or receiving GINA 2018 step 4
treatment with 1 exacerbation/y. This group should be
considered for careful assessment/reassessment in primary care todetermine whether a specialist referral/review is warranted, but
further research is needed to confirm this.
Patients with PSA managed in UK primary care tended to be
female, in their 60s, either current or ex-smokers, and
characterized by high rescue short-acting b2-agonist use, add-on
medications to ICS/LABA therapy, poor lung function and
asthma control, frequent exacerbations, and high
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Online Repository at www.jaci-inpractice.org). Taken together,
these characteristics may help primary care physicians recognize
those with hidden severe asthma in their care, and prompt
referral. Although the older age and smoking history of patients
with PSA may have suggested that some of them had chronic
obstructive pulmonary disease or asthma-chronic obstructive
pulmonary disease overlap, the mean FEV1/forced vital capacity
ratio was 0.78, higher than that reported in the ISAR cohort
(0.66) where asthma has been confirmed. In either case, it is
important to refer these patients with PSA to confirm an asthma
diagnosis, exclude chronic obstructive pulmonary disease,
manage comorbidities, and treat appropriately. Furthermore,
the low rate of current/ex-smokers in the confirmed severe
asthma ISAR cohort may indicate a bias against referring
smokers to severe asthma services. These clinical characteristics
match very well with those reported for patients with severe
asthma managed in secondary and tertiary care in other coun-
tries,25-27 and in the UKSAR,28 providing confidence in the
definition of PSA used in our study. For example, a survey of
104 French pulmonologists, including information from 1502
patients with severe asthma managed in secondary care, found
that these patients were typically in their 50s, more frequently
female, had poorly controlled asthma (despite common ICS
therapy add-ons, eg, leukotriene receptor antagonist and anti-
cholinergics), a high OCS burden, and commonly presented
with ear, nose, and throat comorbidities and a high BEC.25
Similarly, in the United Kingdom, patients with severe asthma
had significantly higher comorbidity rates than those with mild
to moderate disease, for conditions associated with systemic
corticosteroid exposure (eg, type II diabetes mellitus, osteopo-
rosis, dyspeptic disorders, and cataracts).28 However, in the
current study, although patients with asthma referred to tertiary
care were at the severe end of the primary care asthma popula-
tion, their asthma was not as severe as those managed in tertiary
care (ie, UK-ISAR). This is most likely driven by the National
Institute for Health and Care Excellence requirement for 4 or
more exacerbations in the previous 12 months to qualify for
biologic therapy.
In the current study, only 28% of patients in the PSA group
had received specialist care in the previous year. The fate of these
patients warrants further study (eg, % referred back to primary
care; % with severe asthma confirmed). The use of more asthma
therapies, including triple and quadruple therapy regimens,
appeared to be the main driver of referral/review. Interestingly,
asthma control status, lung function, ICS adherence (measured
by medication possession ratio), and BEC profile did not
markedly differ between those with and without a referral.
Furthermore, exacerbation rate was not a referral driver for all
patients with PSA, because many of those referred had not
experienced an exacerbation in the year before referral. Other
studies conducted in the United Kingdom have shown a similar
reticence to refer to specialist care.7,9 The Observational cohort
study to investigate the unmet need and time waiting for referral
for specialist opinion in adult asthma in England study found
that of 19,837 patients with asthma (age 18-65 years) eligible for
referral in the United Kingdom according to British Thoracic
Society/Scottish Intercollegiate Guidelines Network 2016
criteria,28 only 4% were referred during follow-up, with a me-
dian waiting time to specialist care of 2.4 years.7 In addition, the
National Review of Asthma Deaths report (2014) found that ofpatients who had died because of asthma in the United
Kingdom, 47% had not been under specialist supervision during
the 12 months before death.9 Similar findings have been reported
in other countries.8,29-31 For example, the Prevalence, charac-
teristics and management of frequently exacerbating asthma pa-
tients: an observational study in Sweden that included 790
patients with severe asthma in primary care in Sweden found that
more than half of these patients had poor asthma control, but 4
of 5 patients had no contact with secondary care in the previous
year.30 Similarly, results from the Asthma Insight and Manage-
ment Survey conducted in the United States in 2009 including
2500 patients with asthma found that 48% had never visited a
specialist (although some of these may have had mild disease).8
These data indicate an apparent reluctance to refer (and/or be
referred), but further work is needed to understand this behavior.
Possible reasons for lack of referral include clinical inertia;
underestimation of asthma severity and the long-term effects
of OCS, high-dose ICS, and high use of short-acting b2-
agonist32,33; lack of a confirmed asthma diagnosis (many primary
care physicians do not perform confirmatory spirometry);
perception that asthma is a primary care disease; and lack of
awareness, both of newer treatments available at specialist care
(eg, biologics) and of asthma referral guidelines.6 Other barriers
include high referral hurdles (ie, only those with very severe
disease qualify), lack of coordination between different parts of
the health care system,34 patient attitudes/expectations,35
financial pressures,36 and underresourcing; currently, there are
1.86 adult respiratory physicians/100,00 people in the
United Kingdom compared with the European average of 4.4/
100,000.37
Numerous guidelines are available that provide guidance on
when a patient with asthma should be referred to a
specialist.4,28,38 According to the British Thoracic Society
guidelines (2016),28 adults with asthma should be referred to
specialist care in cases of diagnostic uncertainty, if they are high
risk (eg, marked blood eosinophilia, poor response to asthma
treatment at GINA step 4, and/or suffer a severe asthma
exacerbation), if they have a high corticosteroid burden (eg, on
high-dose ICS or continuous/frequent use of OCS), and if
biologics are considered. More than half the patients with PSA in
the current study had never received a specialist referral/review
(since inclusion in OPCRD), despite meeting these criteria,
suggesting there remains a high prevalence of hidden severe
asthma in the United Kingdom. Unfortunately, in real life, pa-
tients with severe asthma often experience several exacerbations
and emergency department admissions before specialist
referral,6,9 and referral can be further delayed by long waiting
times.7 For example, the average time since last referral (for those
patients with PSA who were referred) was 1.89 years in our
study. During this time patients may not receive optimal therapy
for asthma or may be poorly adherent to an optimal treatment
regimen and are often prescribed maintenance OCS or repeated
steroid bursts to treat exacerbations, with potential deleterious
effects.39,40 Although both ICS and OCS have a positive impact
on controlling symptoms and exacerbations,41,42 cumulative
OCS use is associated with increased risk of acute and chronic
adverse events (eg, increased risk of diabetes and osteoporosis),43
increased health care resource use, and increased costs.39 Indeed,
a recently published Swedish study found that the total health
care cost was 3 times greater for patients taking OCS regularly
(V5615) and twice as high for patients taking OCS
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(V1980).44 Similarly, in the United Kingdom, general practice
average annual costs for adverse outcomes and asthma were 42%
greater for patients with active asthma exposed to systemic
corticosteroids (vs those who were not).45
The benefits of a timely and appropriate referral/review by an
asthma specialist are well documented, and include a diagnostic
review, treatment optimization (including immunotherapy and
biologics and improved adherence), and improved self-
management education (eg, inhaler technique). Specialist
review of difficult-to-treat and severe asthma has been associ-
ated not only with an improvement in asthma control, quality
of life, lung function, and exacerbation rate but also with
reduced OCS burden.46,47 Higher costs associated with
specialist review could, thus, be offset against these benefits.
However, not all patients with uncontrolled asthma on
standard-of-care therapy should be referred or have severe
asthma. This is evident in the current study by observed
differences in the demographic and clinical characteristics of
patients with PSA who were referred from primary care in the
last year and those with a confirmed severe asthma diagnosis
managed in tertiary care. Before referral, primary care physi-
cians should play a key role in “referral triage,” assessing their
patients with asthma using a structured methodology (eg,
Smoking status, Inhaler technique, Monitoring, Pharmaco-
therapy, Lifestyle, Education, Support approach)5 and selecting
only those with an accurate asthma diagnosis who continue to
have poor control despite guideline-directed therapy, good
adherence and inhaler technique, and appropriate management
of any comorbidities.5,48 Such an approach would avoid un-
necessary treatment step-up, streamline asthma assessment at
the primary care level, and optimize referrals to specialist care.
Shared decision making should be encouraged to facilitate
patient-centered care that ensures patients with severe asthma
get the right treatment, at the right time, and for the right
reason(s).
One limitation of the current study is the use of prescription
data to define PSA with the assumptions that medications were
(1) prescribed correctly in line with GINA 2018 recommen-
dations and (2) taken as directed. Furthermore, OCS burden
was not used to define severity due to difficulties in differenti-
ating between long-term and acute use in the OPCRD. In
addition, although the presence of a referral code in the OPCRD
provided a clear indication of the referral status of patients (and
time since last referral), no data were captured on the reason(s)
for referral, pathway to referral (eg, from primary care and A&E
department), and/or whether the patient attended. Knowledge
of referral reasons would allow cross-reference with British
Thoracic Society/Scottish Intercollegiate Guidelines Network
referral criteria28 to assess compliance with recommendations.
Knowledge of the referral pathway and “did not attend”
prevalence could provide a more accurate estimation of the true
prevalence of hidden severe asthma in UK primary care. Finally,
information on the type of respiratory specialist referred to (and
their level of asthma expertise) is not captured by OPCRD. To
counterbalance these limitations, it should be noted that,
because of its size, the OPRCD enabled us to identify and study
a large cohort of patients with PSA managed in UK primary
care. Data contained within the OPCRD come from electronic
medical records and have been used frequently for observational
research.49-51 These data provide a snapshot of patients withasthma managed in real life in practices all over the United
Kingdom. Finally, by virtue of the number of disease-specific
variables collected by OPRCD, we were able to compare
patient cohorts using a comprehensive list of demographic and
clinical characteristics.CONCLUSIONS
There are large numbers of patients with asthma in the United
Kingdom with PSA who are managed long-term in primary care
who, after specialist assessment, may be eligible for biologic
therapy. These patients would benefit from a structured assess-
ment by their primary care physician (Smoking status, Inhaler
technique, Monitoring, Pharmacotherapy, Lifestyle, Education,
Support),5 with referral to specialist care if appropriate. A stan-
dard national asthma template would be useful to facilitate a
structured asthma review at the primary care level (with input
from other health care providers, eg, pharmacists and asthma
nurses) to help identify those patients who would most benefit
from specialist review. Further work is necessary to determine
reasons for, and barriers to, specialist referral in the United
Kingdom, how many of those patients referred have severe
asthma, and the fate of patients discharged from specialist care, or
who continue to be managed long-term in primary care.
Combining primary and tertiary care data in severe asthma
registries is one way to answer these questions. This would enable
better monitoring of patients over their disease life cycle, facili-
tate tracking through the health care system—from primary to
tertiary care and back again—improve communication between
primary physicians and tertiary specialists, and improve the
quality of care for patients with severe asthma.REFERENCES
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Appendix
Optimum Patient Care Research Database. At the time
this study was conducted, OPCRD contained anonymous, lon-
gitudinal records from June 1930 to March 2019. Quality of care
for patients with asthma is encouraged for General Practitioner
practices in the United Kingdom through the quality and out-
comes framework initiative, by incentivizing collection of key
clinical metrics (including asthma review and assessment of asthma
control).E1 OPCRD benefits from a long retrospective period
(mean time in the database is 13 years, going back to birth forsummary diagnostic data in 44% of cases), and contains linked
patient-completed respiratory questionnaires for approximately
10% of patients with asthma included.E2 The OPCRD is
approved by the UK National Health Service for clinical research
use (Research Ethics Committee reference 15/EM/0150).
The OPCRD is approved by the Health Research Authority
for clinical research use and governed by the Anonymized Data
Ethics and Protocols Transparency Committee.E3 The Anony-
mized Data Ethics and Protocols Transparency Committee is an
independent body of experts and regulators commissioned by the
Respiratory Effectiveness Group to govern the standard of
research conducted on internationally recognized databases.E4
TABLE E1. Definition of demographic and clinical outcomes
Variable name Description
Demographic outcomes
Age Age in years
Defined at the start of the most recent year of data
Sex Female or male




 South East Asian
 North East Asian
 Not specified
Height Defined as the patient’s most recent height data recorded in their clinical records
BMI The ratio of weight (kg) to height2 (m2).
Defined by either a BMI recorded as part of the patient’s clinical record or calculated using the most recent
height and weight data.
Categorized as
 underweight (<18.5 kg/m2)
 normal weight (18.5 kg/m2 and <25 kg/m2)
 overweight (25 kg/m2 and <30 kg/m2)
 obese (30 kg/m2)
Smoking status Patient’s most recent smoking status.
Defined by most recent patient’s clinical smoking recording. Patients’ records with a “never” recording






No. of exacerbations No. of asthma exacerbations requiring OCSs during the study period
Exacerbation in the year A count of exacerbations/y
Asthma control OPCRD Patients
1. RCP Asthma 3-Questions.E6
Defined by clinical records of RCP control within the latest year of data. Patients are classified as having
poor control if 2 or 3 of the measures denote poor control or if patients experience difficulty sleeping
because of their asthma symptoms
2. ACTE7
Defined by clinical records using the ACT questionnaire within the latest year of data.
 ACT score 19—Not controlled
 ACT score 20-24—Reasonably controlled
 ACT score 25—Controlled
3. Control measured by SABA use: Use of >3.65 SABA canisters in a year indicates poor asthma controlE8
4. Risk Domain Asthma Control: Uncontrolled if any of the following occur in a 12-mo assessment periodE9:
 Primary care exacerbation Read Code
 Acute use of OCS with evidence of lower respiratory tract consultation
 Antibiotics prescribed with evidence of lower respiratory tract consultation
ISAR patients
Categorized according to the ACQ.E10 The 7-item ACQ was developed to measure the primary goals of asthma
management as identified by international guidelines.
Categorized as:
 ACQ score 0.75—Controlled
 ACQ score >0.75-1.25—Partial control
 ACQ score >1.25—Not controlled
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FEV1 (taken at the same
time as an asthma
review)
Maximum forced expiratory volume (FEV1) in the first second of expiration within the last 5 y of available
data
% Predicted FEV1 Predicted value of FEV1 standardized according to ethnicity, age, sex, and height using GLI 2012
FVC (taken at the same
time as an asthma
review)
Maximum FVC within the last 5 y of available data
% Predicted FVC Predicted value of FVC standardized according to ethnicity, age, sex, and height using GLI 2012
FEV1/FVC ratio (taken at
the same time as an
asthma review)
Measured FEV1 as a ratio of measured FVC
PEF (taken at the same time
as an asthma review)
PEF (L/min) recorded using Read Code within the last year of available data
% Predicted PEF Predicted value of PEF standardized according to ethnicity, age, sex, and height.
Categorized as
 % Predicted PEF—0%-50%
 % Predicted PEF—>50%-80%
 % Predicted PEF—>80%
FENO test Measurements of FENO concentration in exhaled breath, measured in ppb at a flow rate of 50 mL/s within the
last 5 y of available data. Categorized as
 low (<25 ppb)
 intermediate (25-50 ppb)
 high (>50 ppb)
MPR (surrogate marker for
adherence in OPCRD
only)
Good adherence to treatment defined as an MPR 70%, measure based on ICS prescription refills
Adherence in ISAR In response to the question, “Is there evidence of poor adherence?,” which is answered as either
 clinical impression
 prescription records
 objective measures (eg, evidence of FENO suppression) or
 no









considered at any point
in time except for
anxiety/depression,
which is considered only








ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; BMI, body mass index; FENO, fractional exhaled nitric oxide; FVC, forced vital capacity; LAMA, long-acting
muscarinic receptor antagonist; LTRA, leukotriene receptor antagonist;MPR, medication possession ratio; PEF, peak expiratory flow; ppb, parts per billion; RCP, Royal College
of Physicians; SABA, short-acting b2-agonist.
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TABLE E2. Summary of asthma treatments by GINA (2018) step
GINA (2018)
treatment step Asthma treatment
Step 1  Only b-agonist or
 Only muscarinic agonist
Step 2  Low-dose ICS without other controllers or
 LTRA without other controllers or
 Low-dose theophylline all without other
controllers
Step 3  Medium- or high-dose ICS without other
controllers or
 Low-dose ICS/LABA or
 Low-dose ICS/LAMA or
 Low-dose ICS (without LABA/LAMA) and/
or theophylline or
 LABA and/or LAMA (without ICS) or
 LTRA plus theophylline (without ICS)
Step 4  Medium- or high-dose ICS/LABA or
 Medium- or high-dose ICS/LAMA or
 Medium- or high-dose ICS plus LTRA and/or
theophylline or
 3 controllers (without ICS)
Step 5  Maintenance OCS plus any other asthma
treatment or
 Anti-IgE therapy
LAMA, Long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist.
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TABLE E3. Demographic and clinical characteristics of patients with asthma in primary care (OPCRD) for those patients 18 y or older
with and without a >5-y OPCRD look-back period
Characteristic
OPCRD potential severe asthma NOT
REFERRED to specialist care




With > 5-y look-back
period




(n [ 11,701) (n [ 9,918) (n [ 4,634) (n [ 3,888)
Age (y)
Mean (95% CI) 62 (62.2-62.8) 63.9 (63.6-64.3) 63 (62.4-63.4) 64.3 (63.7-64.8)
Median (25th, 75th percentile) 65 (51, 76) 66 (53, 77) 65 (51, 76) 67 (53, 77)
Sex, n (%)
Male 4,052 (34.6) 3,456 (35) 1,615 (35) 1,370 (35)
Female 7,640 (65) 6,454 (65) 3,019 (65) 2,526 (65)
Ethnicity
White, n (% nonmissing) 3,137 (61.8) 2,595 (61.0) 1,814 (61.0) 1,488 (60.4)
Black, n (%) 46 (0.9) 35 (0.8) 46 (1.6) 33 (1.3)
Asian, n (%) 1 (0.0) 1 (0.0) 2 (0.1) 2 (0.1)
Mixed/other, n (%) 22 (0.4) 17 (0.4) 14 (0.5) 10 (0.4)
Unknown, n (%) 1,873 (36.9) 1,611 (37.8) 1,093 (37.0) 928 (37.8)
Missing, n (% all records) 6,613 (56.6) 5,651 (57.0) 1,674 (36.1) 1,434 (36.8)
BMI (kg/m2)
Mean (95% CI) 29.2 (29.1-29.4) 29.3 (29.1-29.4) 29.3 (29.1-29.4) 29.4 (29.1-29.6)
Median (25th, 75th percentile) 28.2 (24.3, 33.1) 28.2 (24.3, 33.1) 28.3 (24.2, 33.4) 28.2 (24.2, 33.2)
BMI categories
Underweight (<18.5), n (%
nonmissing)
315 (3.0) 272 (3.1) 130 (3.3) 107 (3.2)
Normal weight (18.5 &
<25), n (% nonmissing)
2,723 (26.3) 2,302 (26.0) 1,028 (26.1) 873 (26.3)
Overweight (25 & <30), n
(% nonmissing)
3,240 (31.2) 2,776 (31.4) 1,189 (30.1) 1,008 (30.3)
Obese (30), n (%
nonmissing)
4,096 (39.5) 3,505 (39.6) 1,594 (40.5) 1,334 (40.2)
Missing, n (% all records) 1,318 (11.3) 1,055 (10.7) 702 (15.1) 574 (14.7)
Smoking status
Never, n (% nonmissing) 2,908 (25.0) 2,311 (23.3) 1,003 (23.4.7) 803 (20.7)
Current, n (% nonmissing) 2,453 (21.1) 1,981 (20.0) 912 (19.8) 721 (18.6)
Ex-smoker, n (% nonmissing) 6,265 (53.9) 5,577 (56.3) 2,697 (58.5) 2,356 (60.7)
Missing, n (% all records) 66 (0.6) 41 (0.4) 31 (0.7) 16 (0.4)
Exacerbations (1 y after referral)
Mean (95% CI) 2.36 (2.33-2.39) 2.35 (2.31-2.39) 3.22 (3.15-3.28) 3.2 (3.13-3.28)
Median (25th, 75th percentile) 2 (2, 3) 2 (2, 3) 3 (2, 4) 3 (2, 4)
Exacerbation per year, n (%)
0 2,033 (17.4) 1,771 (17.9) 286 (6.0) 254 (6.4)
1 632 (5.4) 551 (5.6) 265 (5.7) 226 (5.8)
2 4,657 (39.8) 3,895 (39.3) 1,609 (34.8) 1,346 (34.6)
3 2,100 (17.9) 1,774 (17.9) 952 (20.5) 797 (20.5)
4 1,168 (10.0) 975 (9.8) 588 (12.6) 489 (12.6)
5 1,102 (9.4) 945 (9.5) 943 (20.3) 783 (20.1)
Asthma control,* RCP
Questionnaire
Controlled, n (% nonmissing) 2,303 (46.3) 2011 (46.8) 1,010 (34.5) 852 (35.0)
Partial control, n (%
nonmissing)
— — — —
Not controlled, n (%
nonmissing)
2,673 (53.7) 2,282 (53.2) 1,916 (65.5) 1,586 (65.0)
Missing, n (% all records) 6,716 (57.4) 5617 (56.7) 1,717 (37.0) 1,458 (37.4)
Asthma control,† ACT
(continued)





OPCRD potential severe asthma NOT
REFERRED to specialist care




With > 5-y look-back
period




(n [ 11,701) (n [ 9,918) (n [ 4,634) (n [ 3,888)
Well controlled, n (%
nonmissing)
57 (8.7) 51 (9.1) 19 (4.3) 14 (3.9)
Reasonably controlled, n (%
nonmissing)
260 (39.5) 219 (39.2) 148 (33.3) 122 (33.9)
Not controlled, n (%
nonmissing)
341 (51.8) 289 (51.7) 278 (62.5) 224 (62.2)
Missing, n (% all records) 11,034 (94.3) 9,351 (94.4) 4,198 (90.4) 3,536 (90.7)
Control measured by SABA use,
n (%)
<4 inhalers—No evidence of
lack of control
4,270 (36.2) 3,360 (36.9) 1,429 (30.7) 1,222 (31.3)
4 inhalers—Not controlled 7,422 (63.8) 6,250 (63.1) 3,214 (69.3) 2,674 (68.7)
Risk Domain Asthma Control, n
(%)
Controlled 1,586 (13.6) 1,378 (13.9) 333 (7.1) 285 (92.8)
Not controlled 10,106 (86.4) 8,532 (86.1) 4,310 (92.9) 3,611 (7.3)
BEC
Mean (95% CI) 295 (289-301) 296 (289-304) 299 (285-312) 299 (284-314)
Median (25th, 75th percentile) 230 (152, 350) 232 (155, 350) 230 (153, 342) 230 (155, 343)
0.15, n (% nonmissing) 2,595 (23.3) 2,169 (22.7) 1,021 (23.0) 861 (22.8)
>0.15-0.3, n (% nonmissing) 4,659 (41.9) 4,078 (42.6) 1,930 (43.4) 1,644 (43.6)
>0.3-0.45, n (% nonmissing) 2,236 (20.1) 1,920 (20.1) 881 (19.8) 760 (20.1)
>0.45, n (% nonmissing) 1,624 (14.7) 1,359 (14.6) 619 (13.8) 513 (13.5)
Missing, n (% all records) 578 (4.9) 348 (3.5) 192 (4.1) 118 (3.0)
Postbronchodilator FEV1
Mean (95% CI) 1.85 (1.83-1.87) 1.83 (1.80-1.84) 1.77 (1.74-1.80) 1.75 (1.72-1.79)
Missing, n (% all records) 6,557 (56.1) 5,398 (54.5) 2,243 (48.3) 1,815 (46.5)
% Predicted postbronchodilator
FEV1z
Mean (95% CI) 0.72 (0.71-0.72) 0.75 (0.71-0.72) 0.69 (0.68-0.70) 0.68 (0.67-0.69)
Postbronchodilator FVC
Mean (95% CI) 2.81 (2.78-2.84) 2.79 (2.76-2.82) 2.73 (2.69-2.78) 2.71 (2.66-2.75)
% Predicted postbronchodilator
FVCz
Mean (95% CI) 0.85 (0.84-0.85) 0.85 (0.84-0.85) 0.82 (0.81-0.83) 0.82 (0.81-0.83)
Postbronchodilator FEV1/FVC
ratio
Mean (95% CI) 0.67 (0.67-0.68) 0.67 (0.66-0.67) 0.66 (0.65-0.67) 0.66 (0.65-0.66)
% Patients FEV1/FVC ratio
<70%
52.5 53.3 53.4 54.7
Postbronchodilator (PEF)
Mean (95% CI) 321 (318-325) 318 (314-322) 313 (308-318) 309 (304-314)
Postbronchodilator % PPEF
<50%, n (% nonmissing) 261 (10.5) 233 (11.1) 228 (13.6) 195 (14.1)
50%-<80%, n (%
nonmissing)
1,278 (51.3) 1,073 (51.1) 825 (48.9) 690 (49.6)
80%, n (% nonmissing) 954 (38.2) 797 (37.9) 630 (37.5) 505 (36.4)
Missing, n (% all records) 9,199 (78.7) 7,807 (78.8) 2,960 (63.8) 2,506 (64.4)
FENO
Low (<25 ppb), n (%
nonmissing)
1 (33.3) 1 (50.0) 1 (100) 1 (100)
(continued)
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OPCRD potential severe asthma NOT
REFERRED to specialist care




With > 5-y look-back
period




(n [ 11,701) (n [ 9,918) (n [ 4,634) (n [ 3,888)
Intermediate (25-50 ppb), n (%
nonmissing)
2 (66.7) 1 (50.0) 0 (0.0) 0 (0.0)
High (>50 ppb), n (%
nonmissing)
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing, n (% all records) 11,699 (99.9) 9,908 (99.9) 4,624 (99.9) 3,895 (99.9)
Adherence measured using MPR
of ICS,x n (%)
<70% MPR 4,836 (48.4) 4,053 (48.0) 1,878 (43.8) 1,576 (43.4)
70% MPR 5,152 (51.6) 4,390 (52.0) 2,407 (56.2) 2,008 (56.0)
Medication, n (%)
ICS/LABA 5,312 (45.4) 4,479 (45.2) 1,753 (37.8) 1,461 (37.5)
ICS/LABA/LTRA 1,957 (16.8) 1,620 (16.3) 871 (18.9) 699 (17.9)
ICS/LABA/LAMA 1,982 (16.9) 1,717 (17.3) 1,117 (24.0) 971 (25.0)
ICS/LABA/LAMA/LTRA 714 (6.1) 612 (6.2) 525 (11.2) 440 (11.3)
SABA 10,149 (86.9) 8,596 (86.7) 4,187 (90.3) 3,502 (90.0)
Theophylline 930 (8.0) 804 (8.1) 638 (13.7) 540 (13.8)
Biologic treatments 0 (0.0) 0 (0.0) 19 (0.4) 15 (0.4)
Comorbidities,* n (%)
Allergic rhinitis 3,638 (31.1) 3,202 (27.3) 1,240 (26.7) 1,109 (28.5)
Eczema 3,794 (32.4) 3,341 (28.6) 1,447 (31.2) 1,298 (33.3)
Nasal polyps 799 (6.9) 702 (6.0) 319 (6.8) 281 (7.2)
Anxiety/depression 97 (0.8) 79 (0.7) 39 (0.8) 31 (0.8)
Diabetes 1,058 (9.0) 948 (8.1) 585 (12.6) 530 (12.6)
Osteoporosis 928 (7.9) 833 (7.1) 431 (9.3) 390 (10.0)
Heart failure 424 (3.6) 383 (3.3) 212 (4.6) 196 (5.0)
ACT, Asthma Control Test; FENO, fractional exhaled nitric oxide; FVC, forced vital capacity; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist;
MPR, medication possession ratio; ppb, parts per billion; PEF, peak expiratory flow; PPEF, percent predicted peak expiratory flow; RCP, Royal College of Physicians; SABA,
short-acting b2-agonist.
*Differences most likely due to the selection criteria for ISAR which requires patients receiving Reslizumab to have 3 exacerbations whilst Benralizumab and mepolizumab
require 4 exacerbations before initiation.
†Different co-morbidity rates likely due to self-reporting data capture.
zPost-referral.
xBefore referral.
J ALLERGY CLIN IMMUNOL PRACT
APRIL 2021
1623.e7 RYAN ETAL
FIGURE E1. Time since last specialist consultation for patients with potentially severe asthma but no referral record in the last year
(n ¼ 2628).
TABLE E4. Similarities and differences between patients with PSA (referred and nonreferred) and those with confirmed severe asthma
Characteristic
Primary care (OPCRD) Tertiary care (UK-ISAR)
PSA NOT reviewed or referred in
specialist care (‡16 y)
PSA REVIEWED/REFERRED in
specialist
care (aged ‡16 y)
Confirmed severe asthma (aged ‡ 18
y)
Age (y) Likely in 60s Likely in 60s Likely in 50s
Sex Likely female: 65% Likely female: 65% Likely female: 64%
Obesity Likely obese: 39% Likely obese: 40% More likely obese (48%)
Ethnicity Predominantly white (62%) or unknown
race (37%)
Predominantly white (61%) or
unknown race (37%)
Predominantly white (68%) but
greater race diversity
Smoking Likely an ex-smoker (54%) or current
smoker (21%)
Likely an ex-smoker (58%) or current
smoker (20%)
Likely to have never smoked (69%)
Medication Equal likelihood of ICS/LABA (45%) or
ICS/LABA
plus other treatment (40%)
More likely on ICS/LABA plus other
treatment (54%)
Most likely on biologic (55%) and/or
ICS/LABA plus other treatment
(68%)
Adherence* Many have poor adherence (48%) Many have poor adherence (44%) Most have good adherence (73%)
Exacerbations† Likely to have 2 exacerbations/y
3 exacerbations/y (37%)
Likely to have 3z exacerbations/y
3 exacerbations/y (31%)x
Likely to have 4 exacerbations/y
3 exacerbations/y (72%)
Controlǁ Not controlled: 52% Not controlled: 62% Most likely not controlled (91%)
Spirometry{
(postbronchodilator)
FEV1/FVC <0.7: 52% FEV1/FVC <0.7: 53% FEV1/FVC <0.7: 56%
Comorbidity#,** Nasal polyps unlikely (7%) Nasal polyps unlikely (7%) Nasal polyps more likely (24%)
FVC, Forced vital capacity; PSA, potential severe asthma.
*OPCRD adherence measured by medication possession ratio. Poor adherence indicated by <70% days prescribed. ISAR poor adherence indicated using prescription records
and clinical impression.
†Differences most likely due to the selection criteria for ISAR, which requires patients receiving reslizumab to have 3 exacerbations, whereas benralizumab and mepolizumab
require 4 exacerbations before initiation.
zPostreferral.
xBefore referral.
ǁControl scores based on Asthma Control Test.
{Spirometry readings based on average maximum value over the preceding 5 y.
#OPCRD comorbidities based on ever having a diagnosis.
**Different comorbidity rates likely due to self-reporting data capture.
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FIGURE E2. Asthma control status (assessed by Asthma Control Test) of patients in each cohort. PSA, Potential severe asthma; UK-
ISAR, UK patients in the ISAR.
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